N/A Completed N=10 Other

A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine

Source: ClinicalTrials.gov NCT02485964 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2021

Primary outcomePrimary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants

Summary

To measure antigen-specific interferon-secretion by enzyme-linked immunospot (ELISPOT) assay, which measures antigen-specific interferon-secretion.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay	4	—

Eligibility Criteria

Inclusion Criteria

Histological documented diagnosis of prostate cancer
18 years of age or older
Signed informed consent form approved by the University of Arkansas for Medical Sciences (UAMS) Institutional Review Board (IRB)

Exclusion Criteria

Subjects must have no other current malignancies.
Subjects with prior history at any time of any basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration.
Subjects with other malignancies are eligible if they have been continuously disease free for ≥ 5 years prior to the time of registration

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02485964). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.